JP2025522295A5 - - Google Patents
Info
- Publication number
- JP2025522295A5 JP2025522295A5 JP2024569265A JP2024569265A JP2025522295A5 JP 2025522295 A5 JP2025522295 A5 JP 2025522295A5 JP 2024569265 A JP2024569265 A JP 2024569265A JP 2024569265 A JP2024569265 A JP 2024569265A JP 2025522295 A5 JP2025522295 A5 JP 2025522295A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- antibody
- antigen
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263345016P | 2022-05-23 | 2022-05-23 | |
| US63/345,016 | 2022-05-23 | ||
| US202263427799P | 2022-11-23 | 2022-11-23 | |
| US63/427,799 | 2022-11-23 | ||
| US202263430319P | 2022-12-05 | 2022-12-05 | |
| US63/430,319 | 2022-12-05 | ||
| US202363481977P | 2023-01-27 | 2023-01-27 | |
| US63/481,977 | 2023-01-27 | ||
| US202363488433P | 2023-03-03 | 2023-03-03 | |
| US63/488,433 | 2023-03-03 | ||
| US202363493057P | 2023-03-30 | 2023-03-30 | |
| US63/493,057 | 2023-03-30 | ||
| PCT/US2023/067312 WO2023230445A2 (en) | 2022-05-23 | 2023-05-22 | Broadly neutralizing antibodies against influenza neuraminidase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025522295A JP2025522295A (ja) | 2025-07-15 |
| JP2025522295A5 true JP2025522295A5 (enExample) | 2026-05-01 |
Family
ID=86904151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024569265A Pending JP2025522295A (ja) | 2022-05-23 | 2023-05-22 | インフルエンザノイラミニダーゼに対する広域中和抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20260184814A1 (enExample) |
| EP (1) | EP4529464A2 (enExample) |
| JP (1) | JP2025522295A (enExample) |
| KR (1) | KR20250030975A (enExample) |
| CN (1) | CN119907679A (enExample) |
| AU (1) | AU2023277611A1 (enExample) |
| CA (1) | CA3256285A1 (enExample) |
| TW (1) | TW202411247A (enExample) |
| WO (1) | WO2023230445A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026021428A1 (en) * | 2024-07-23 | 2026-01-29 | Westlake University | Anti-neuraminidase antibodies and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| WO2005028515A1 (ja) | 2003-09-24 | 2005-03-31 | Kyowa Hakko Kogyo Co., Ltd. | ヒトインスリン様成長因子に対する遺伝子組換え抗体 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| AU2014374055B2 (en) | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| US10174127B2 (en) * | 2015-02-05 | 2019-01-08 | Janssen Vaccines & Prevention B.V. | Human neutralizing antibodies binding to influenza neuraminidase |
| US11267899B2 (en) | 2015-05-13 | 2022-03-08 | Zumutor Biologics Inc. | Afucosylated protein, cell expressing said protein and associated methods |
| WO2019024979A1 (en) | 2017-07-31 | 2019-02-07 | Institute For Research In Biomedicine | FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION |
| CN117843810A (zh) | 2017-09-22 | 2024-04-09 | 上海药明生物技术有限公司 | 新型双特异性多肽复合物 |
| BR112022026316A2 (pt) | 2020-06-24 | 2023-03-07 | Vir Biotechnology Inc | Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos |
| PH12023551390A1 (en) * | 2020-11-23 | 2023-12-04 | Humabs Biomed Sa | Broadly neutralizing antibodies against influenza neuraminidase |
-
2023
- 2023-05-22 US US18/868,143 patent/US20260184814A1/en active Pending
- 2023-05-22 CA CA3256285A patent/CA3256285A1/en active Pending
- 2023-05-22 AU AU2023277611A patent/AU2023277611A1/en active Pending
- 2023-05-22 WO PCT/US2023/067312 patent/WO2023230445A2/en not_active Ceased
- 2023-05-22 KR KR1020247042571A patent/KR20250030975A/ko active Pending
- 2023-05-22 EP EP23733557.5A patent/EP4529464A2/en active Pending
- 2023-05-22 TW TW112118976A patent/TW202411247A/zh unknown
- 2023-05-22 CN CN202380053083.8A patent/CN119907679A/zh active Pending
- 2023-05-22 JP JP2024569265A patent/JP2025522295A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11787860B2 (en) | Anti-CD47 antibodies and uses thereof | |
| US10544212B2 (en) | Anti-IL-33 antibodies, compositions, methods and uses thereof | |
| US12076413B2 (en) | Compositions and methods for modulating delta gamma chain mediated immunity | |
| US20230112916A1 (en) | Neutralizing anti-influenza binding molecules and uses thereof | |
| AU2016214304A1 (en) | Binding molecules directed against influenza hemagglutinin and uses thereof | |
| US12331104B2 (en) | Hepatitis B antibodies | |
| JP6162319B2 (ja) | ヒト化抗ｎ２抗体 | |
| US20240092875A1 (en) | Sars-cov-2 antibodies for treatment and prevention of covid-19 | |
| JP2023551668A5 (enExample) | ||
| CN115551885A (zh) | 用于治疗和预防流感的组合物和方法 | |
| TW202342095A (zh) | 用於治療和預防ｃｏｖｉｄ—１９之組成物 | |
| CA3199429A1 (en) | Anti-influenza antibodies and combinations thereof | |
| CA3199023A1 (en) | Broadly neutralizing antibodies against influenza neuraminidase | |
| JP2023551666A5 (enExample) | ||
| CA3197537A1 (en) | Antibodies against influenza a viruses | |
| US20250154287A1 (en) | ANTI-MIGIS-alpha ANTIBODIES AND METHODS OF USE THEREOF | |
| US20250376511A1 (en) | BINDING PROTEINS THAT TARGET aC1s, TfR, OR BOTH, AND COMPOSITIONS THEREOF | |
| US12071481B2 (en) | Anti-CD47 antibodies and uses thereof | |
| US20260035439A1 (en) | Anti-Sars-COV-2 Antibodies and Uses Thereof | |
| WO2026021428A1 (en) | Anti-neuraminidase antibodies and uses thereof | |
| JP2025094941A (ja) | Ｌａｇ－３アゴニスト抗体 |